logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11911469 B1

PDFFull Text
Date of Patent:
Feb. 27, 2024

Filed:

Jan. 11, 2017

Combination of acat1 inhibitor and checkpoint antibody for treating cancer

Applicant:

Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, CN;

Inventors:

Chenqi Xu, Shanghai, CN;

Boliang Li, Shanghai, CN;

Wei Yang, Shanghai, CN;

Yibing Bai, Shanghai, CN;

Ying Xiong, Shanghai, CN;

Assignee:

Center for Excellence in Molecular Cell Science, Chinese Academy of Scienes, Shanghai, CN;

Attorney:

Banner & Witcoff, Ltd.

Primary Examiner:

Misook Yu

Assistant Examiner:

Cheng Lu

Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61K 31/18 (2006.01); A61K 31/655 (2006.01); C07K 16/28 (2006.01); A61P 35/00 (2006.01); A61K 31/44 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 31/18 (2013.01); A61K 31/44 (2013.01); A61K 31/655 (2013.01); A61K 39/395 (2013.01); A61K 39/3955 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01);
Abstract

The present disclosure provides methods and compositions for the treatment of cancer using an ACAT1 inhibitor in combination with an immune checkpoint inhibitor. The immune checkpoint inhibitor may inhibit the programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), lymphocyte-activation protein 3 (LAG-3), or combinations thereof. The ACAT1 inhibitor may be avasimibe, pactimibe, or purpactins, without limitation.

Find Patent Forward Citations

Xu, Chenqi. (2024). Combination of acat1 inhibitor and checkpoint antibody for treating cancer (U.S. Patent No. 11911469). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/11911469

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…